FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza, Healthy
Trial Timeline
May 8, 2017 → Sep 29, 2017
NCT ID
NCT03143101About FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018) is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT03143101. Target conditions include Influenza, Healthy.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03143101 | Approved | Completed |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| VAL-339851 | Moderna | Phase 1 | 0 |
| mRNA-1018-H5 | Moderna | Phase 3 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |